Document Detail


Association between etanercept use and employment outcomes among patients with rheumatoid arthritis.
MedLine Citation:
PMID:  14613265     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To assess the association between use of etanercept and employment outcomes among patients with rheumatoid arthritis (RA). METHODS: In 1999, 497 RA patients of working ages (18-64 years) reported their employment status in the year of diagnosis and as of the study year, in structured telephone interviews. Of these, 238 had been in clinical trials of etanercept and were currently taking that medication, while 259 were members of an observational study and were not taking etanercept. We used regression techniques to estimate whether employment outcomes in 1999 (employed versus not and, among the employed, hours of work per week, weeks of work per year, and hours of work per year) among the 379 of the 497 patients who were employed at the time of diagnosis were associated with etanercept use, with and without adjustment for demographic characteristics, RA status, overall health status, and the nature of the job held at the time of diagnosis. RESULTS: At the time of diagnosis, 75% of RA patients from the observational study who did not take etanercept and 77% of those who did take the medication were employed. By 1999, among those employed at diagnosis, 55% of the former group and 71% of the latter were employed (difference 16 percentage points). After adjustment for demographics, overall health status, duration of RA, RA status, and occupation and industry, the difference widened to 20 percentage points. Among all who were employed at the time of diagnosis, those from the etanercept clinical trials worked an average of 5.4 more hours per week in 1999; after adjustment, the etanercept group worked 7.4 more hours per week. CONCLUSION: Among all persons who were employed at the time of RA diagnosis, having been in the etanercept clinical trials was associated with higher employment rates in 1999 and a greater number of hours per week of work in that year, suggesting that a randomized trial to establish the relationship between treatment and employment outcomes is now warranted.
Authors:
Edward Yelin; Laura Trupin; Patricia Katz; Deborah Lubeck; Stephanie Rush; Lee Wanke
Related Documents :
8992005 - Quantitative analysis of hand radiographs in rheumatoid arthritis: time course of radio...
20349395 - Problematic social support, family functioning, and subjective well-being in women with...
17278015 - Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in acti...
15170915 - Radiographic hand joint space width assessed by computer is a sensitive measure of chan...
922265 - Symptom changes in chronic schizophrenic patients on a token economy: a controlled expe...
24677125 - Psychological distress in families of victims of maritime piracy - the italian experience.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Arthritis and rheumatism     Volume:  48     ISSN:  0004-3591     ISO Abbreviation:  Arthritis Rheum.     Publication Date:  2003 Nov 
Date Detail:
Created Date:  2003-11-12     Completed Date:  2003-12-02     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0370605     Medline TA:  Arthritis Rheum     Country:  United States    
Other Details:
Languages:  eng     Pagination:  3046-54     Citation Subset:  AIM; IM    
Affiliation:
Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco, California 94143-0920, USA. yelin2@itsa.ucsf.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Antirheumatic Agents / therapeutic use*
Arthritis, Rheumatoid / drug therapy*,  physiopathology
Disability Evaluation*
Employment*
Female
Health Status
Humans
Immunoglobulin G / therapeutic use*
Male
Middle Aged
Receptors, Tumor Necrosis Factor / therapeutic use*
Severity of Illness Index
Grant Support
ID/Acronym/Agency:
AR-20684/AR/NIAMS NIH HHS
Chemical
Reg. No./Substance:
0/Antirheumatic Agents; 0/Immunoglobulin G; 0/Receptors, Tumor Necrosis Factor; 185243-69-0/TNFR-Fc fusion protein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Prognostic factors in a large cohort of patients with early undifferentiated inflammatory arthritis ...
Next Document:  Coffee consumption and risk of rheumatoid arthritis.